000005578512/312022Q3FALSE00000557852022-01-012022-09-300000055785us-gaap:CommonStockMemberexch:XNYS2022-01-012022-09-300000055785kmb:A0.625NotesDue2024Memberexch:XNYS2022-01-012022-09-3000000557852022-10-18xbrli:shares00000557852022-07-012022-09-30iso4217:USD00000557852021-07-012021-09-3000000557852021-01-012021-09-30iso4217:USDxbrli:shares00000557852022-09-3000000557852021-12-310000055785us-gaap:CommonStockMember2022-06-300000055785us-gaap:AdditionalPaidInCapitalMember2022-06-300000055785us-gaap:TreasuryStockMember2022-06-300000055785us-gaap:RetainedEarningsMember2022-06-300000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000055785us-gaap:NoncontrollingInterestMember2022-06-3000000557852022-06-300000055785us-gaap:RetainedEarningsMember2022-07-012022-09-300000055785us-gaap:NoncontrollingInterestMember2022-07-012022-09-300000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000055785us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000055785us-gaap:TreasuryStockMember2022-07-012022-09-300000055785us-gaap:TreasuryStockMember2021-07-012021-09-300000055785us-gaap:CommonStockMember2022-09-300000055785us-gaap:TreasuryStockMember2022-09-300000055785us-gaap:NoncontrollingInterestMember2022-09-300000055785us-gaap:CommonStockMember2021-12-310000055785us-gaap:AdditionalPaidInCapitalMember2021-12-310000055785us-gaap:TreasuryStockMember2021-12-310000055785us-gaap:RetainedEarningsMember2021-12-310000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000055785us-gaap:NoncontrollingInterestMember2021-12-310000055785us-gaap:RetainedEarningsMember2022-01-012022-09-300000055785us-gaap:NoncontrollingInterestMember2022-01-012022-09-300000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000055785us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000055785us-gaap:TreasuryStockMember2022-01-012022-09-300000055785us-gaap:TreasuryStockMember2021-01-012021-09-300000055785us-gaap:AdditionalPaidInCapitalMember2022-09-300000055785us-gaap:RetainedEarningsMember2022-09-300000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000055785us-gaap:CommonStockMember2021-06-300000055785us-gaap:AdditionalPaidInCapitalMember2021-06-300000055785us-gaap:TreasuryStockMember2021-06-300000055785us-gaap:RetainedEarningsMember2021-06-300000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000055785us-gaap:NoncontrollingInterestMember2021-06-3000000557852021-06-300000055785us-gaap:RetainedEarningsMember2021-07-012021-09-300000055785us-gaap:NoncontrollingInterestMember2021-07-012021-09-300000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000055785us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000055785us-gaap:CommonStockMember2021-09-300000055785us-gaap:AdditionalPaidInCapitalMember2021-09-300000055785us-gaap:TreasuryStockMember2021-09-300000055785us-gaap:RetainedEarningsMember2021-09-300000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000055785us-gaap:NoncontrollingInterestMember2021-09-3000000557852021-09-300000055785us-gaap:CommonStockMember2020-12-310000055785us-gaap:AdditionalPaidInCapitalMember2020-12-310000055785us-gaap:TreasuryStockMember2020-12-310000055785us-gaap:RetainedEarningsMember2020-12-310000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000055785us-gaap:NoncontrollingInterestMember2020-12-3100000557852020-12-310000055785us-gaap:RetainedEarningsMember2021-01-012021-09-300000055785us-gaap:NoncontrollingInterestMember2021-01-012021-09-300000055785us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000055785us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000055785us-gaap:SalesMemberus-gaap:GeographicConcentrationRiskMemberkmb:KCArgentinaMember2022-01-012022-09-30xbrli:pure0000055785us-gaap:SalesMemberus-gaap:GeographicConcentrationRiskMemberkmb:KCArgentinaMember2021-01-012021-09-300000055785country:TRus-gaap:SalesMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300000055785kmb:ThinxIncMember2022-01-012022-09-300000055785kmb:ThinxIncMember2022-01-012022-03-310000055785kmb:ThinxIncMember2022-03-310000055785kmb:ThinxIncMember2022-09-300000055785kmb:PersonalCareMemberkmb:ThinxIncMember2022-09-300000055785kmb:BeforeTaxMemberkmb:ThinxIncMember2022-01-012022-03-310000055785kmb:ThinxIncMemberkmb:AfterTaxMember2022-01-012022-03-310000055785us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-09-300000055785us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000055785us-gaap:FairValueInputsLevel3Member2022-09-300000055785us-gaap:FairValueInputsLevel3Member2021-12-310000055785us-gaap:FairValueMeasurementsRecurringMemberkmb:NetAssetValueorItsEquivalentMember2022-09-300000055785us-gaap:FairValueMeasurementsRecurringMemberkmb:NetAssetValueorItsEquivalentMember2021-12-310000055785us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2022-09-300000055785us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2022-09-300000055785us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2021-12-310000055785us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2021-12-310000055785us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-09-300000055785us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-300000055785us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-12-310000055785us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310000055785kmb:UnrealizedTranslationMember2020-12-310000055785us-gaap:PensionPlansDefinedBenefitMember2020-12-310000055785us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000055785us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-12-310000055785kmb:UnrealizedTranslationMember2021-01-012021-09-300000055785us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300000055785us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000055785us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-09-300000055785kmb:UnrealizedTranslationMember2021-09-300000055785us-gaap:PensionPlansDefinedBenefitMember2021-09-300000055785us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-09-300000055785us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-09-300000055785kmb:UnrealizedTranslationMember2021-12-310000055785us-gaap:PensionPlansDefinedBenefitMember2021-12-310000055785us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000055785us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-12-310000055785kmb:UnrealizedTranslationMember2022-01-012022-09-300000055785us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000055785us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000055785us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-01-012022-09-300000055785kmb:UnrealizedTranslationMember2022-09-300000055785us-gaap:PensionPlansDefinedBenefitMember2022-09-300000055785us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-09-300000055785us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-09-300000055785us-gaap:InterestRateContractMemberus-gaap:FairValueHedgingMember2022-09-300000055785us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2022-09-300000055785us-gaap:NetInvestmentHedgingMember2022-09-300000055785us-gaap:NondesignatedMember2022-07-012022-09-300000055785us-gaap:NondesignatedMember2021-07-012021-09-300000055785us-gaap:NondesignatedMember2022-01-012022-09-300000055785us-gaap:NondesignatedMember2021-01-012021-09-300000055785us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-09-300000055785kmb:PersonalCareMember2022-07-012022-09-300000055785kmb:PersonalCareMember2021-07-012021-09-300000055785kmb:PersonalCareMember2022-01-012022-09-300000055785kmb:PersonalCareMember2021-01-012021-09-300000055785kmb:ConsumerTissueMember2022-07-012022-09-300000055785kmb:ConsumerTissueMember2021-07-012021-09-300000055785kmb:ConsumerTissueMember2022-01-012022-09-300000055785kmb:ConsumerTissueMember2021-01-012021-09-300000055785kmb:KCProfessionalMember2022-07-012022-09-300000055785kmb:KCProfessionalMember2021-07-012021-09-300000055785kmb:KCProfessionalMember2022-01-012022-09-300000055785kmb:KCProfessionalMember2021-01-012021-09-300000055785us-gaap:CorporateAndOtherMember2022-07-012022-09-300000055785us-gaap:CorporateAndOtherMember2021-07-012021-09-300000055785us-gaap:CorporateAndOtherMember2022-01-012022-09-300000055785us-gaap:CorporateAndOtherMember2021-01-012021-09-300000055785kmb:OtherincomeandexpensenetMember2022-07-012022-09-300000055785kmb:OtherincomeandexpensenetMember2021-07-012021-09-300000055785kmb:OtherincomeandexpensenetMember2022-01-012022-09-300000055785kmb:OtherincomeandexpensenetMember2021-01-012021-09-300000055785kmb:BeforeTaxMemberkmb:PersonalCareMemberkmb:A2018GlobalRestructuringProgramMember2021-07-012021-09-300000055785kmb:BeforeTaxMemberkmb:A2018GlobalRestructuringProgramMemberkmb:ConsumerTissueMember2021-07-012021-09-300000055785kmb:KCProfessionalMemberkmb:BeforeTaxMemberkmb:A2018GlobalRestructuringProgramMember2021-07-012021-09-300000055785kmb:BeforeTaxMemberkmb:PersonalCareMemberkmb:A2018GlobalRestructuringProgramMember2021-01-012021-09-300000055785kmb:BeforeTaxMemberkmb:A2018GlobalRestructuringProgramMemberkmb:ConsumerTissueMember2021-01-012021-09-300000055785kmb:KCProfessionalMemberkmb:BeforeTaxMemberkmb:A2018GlobalRestructuringProgramMember2021-01-012021-09-300000055785kmb:BabyandchildcareproductsMember2022-07-012022-09-300000055785kmb:BabyandchildcareproductsMember2021-07-012021-09-300000055785kmb:BabyandchildcareproductsMember2022-01-012022-09-300000055785kmb:BabyandchildcareproductsMember2021-01-012021-09-300000055785kmb:ConsumerTissueMember2022-07-012022-09-300000055785kmb:ConsumerTissueMember2021-07-012021-09-300000055785kmb:ConsumerTissueMember2022-01-012022-09-300000055785kmb:ConsumerTissueMember2021-01-012021-09-300000055785kmb:KCProfessionalMember2022-07-012022-09-300000055785kmb:KCProfessionalMember2021-07-012021-09-300000055785kmb:KCProfessionalMember2022-01-012022-09-300000055785kmb:KCProfessionalMember2021-01-012021-09-300000055785kmb:AllOtherMember2022-07-012022-09-300000055785kmb:AllOtherMember2021-07-012021-09-300000055785kmb:AllOtherMember2022-01-012022-09-300000055785kmb:AllOtherMember2021-01-012021-09-300000055785kmb:LifoMember2022-09-300000055785kmb:NonLifoMember2022-09-300000055785kmb:LifoMember2021-12-310000055785kmb:NonLifoMember2021-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________  
Commission file number 1-225
kmb-20220930_g1.jpg
KIMBERLY-CLARK CORPORATION
(Exact name of registrant as specified in its charter

Delaware   39-0394230
(State or other jurisdiction of
incorporation)		   (I.R.S. Employer
Identification No.)
P.O. Box 619100
Dallas, TX
75261-9100
(Address of principal executive offices)
(Zip code)
(972) 281-1200
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock KMB New York Stock Exchange
0.625% Notes due 2024 KMB24 New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
x
    Accelerated filer ☐
Non-accelerated filer ☐    Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ☐    No x
As of October 18, 2022, there were 337,492,094 shares of the Corporation's common stock outstanding.


Table of Contents
1
1
1
2
3
4
6
7



PART I – FINANCIAL INFORMATION
Item 1.    Financial Statements
KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS
(Unaudited)
Three Months Ended
September 30		 Nine Months Ended
September 30
(Millions of dollars, except per share amounts) 2022 2021 2022 2021
Net Sales $ 5,053  $ 5,010  $ 15,211  $ 14,475 
Cost of products sold 3,510  3,527  10,619  9,923 
Gross Profit 1,543  1,483  4,592  4,552 
Marketing, research and general expenses 873  819  2,665  2,488 
Other (income) and expense, net 15  7  (42) 24 
Operating Profit 655  657  1,969  2,040 
Nonoperating expense (18) (10) (49) (71)
Interest income 4  1  7  4 
Interest expense (73) (64) (206) (192)
Income Before Income Taxes and Equity Interests 568  584  1,721  1,781 
Provision for income taxes (127) (126) (356) (386)
Income Before Equity Interests 441  458  1,365  1,395 
Share of net income of equity companies 29  21  81  88 
Net Income 470  479  1,446  1,483 
Net income attributable to noncontrolling interests (3) (10) (19) (26)
Net Income Attributable to Kimberly-Clark Corporation $ 467  $ 469  $ 1,427  $ 1,457 
Per Share Basis
Net Income Attributable to Kimberly-Clark Corporation
Basic $ 1.38  $ 1.39  $ 4.23  $ 4.32 
Diluted $ 1.38  $ 1.39  $ 4.22  $ 4.31 
See notes to the unaudited interim consolidated financial statements.

1

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
  Three Months Ended
September 30		 Nine Months Ended
September 30
(Millions of dollars) 2022 2021 2022 2021
Net Income $ 470  $ 479  $ 1,446  $ 1,483 
Other Comprehensive Income (Loss), Net of Tax
   Unrealized currency translation adjustments (316) (151) (530) (288)
   Employee postretirement benefits 20  16  36  45 
   Other 45  35  79  93 
Total Other Comprehensive Income (Loss), Net of Tax (251) (100) (415) (150)
Comprehensive Income 219  379  1,031  1,333 
   Comprehensive (income) loss attributable to noncontrolling interests 9  1  7  (8)
Comprehensive Income Attributable to Kimberly-Clark Corporation $ 228  $ 380  $ 1,038  $ 1,325 
See notes to the unaudited interim consolidated financial statements.

2

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(2022 Data is Unaudited)
(Millions of dollars) September 30, 2022 December 31, 2021
ASSETS
Current Assets
Cash and cash equivalents $ 362  $ 270 
Accounts receivable, net 2,333  2,207 
Inventories 2,281  2,239 
Other current assets 649  849 
Total Current Assets 5,625  5,565 
Property, Plant and Equipment, Net 7,737  8,097 
Investments in Equity Companies 266  290 
Goodwill 2,043  1,840 
Other Intangible Assets, Net 866  810 
Other Assets 1,299  1,235 
TOTAL ASSETS $ 17,836  $ 17,837 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Debt payable within one year $ 959  $ 433 
Trade accounts payable 3,660  3,840 
Accrued expenses and other current liabilities 2,190  2,096 
Dividends payable 388  380 
Total Current Liabilities 7,197  6,749 
Long-Term Debt 7,628  8,141 
Noncurrent Employee Benefits 837  809 
Deferred Income Taxes 636  694 
Other Liabilities 695  681 
Redeemable Common and Preferred Securities of Subsidiaries 260  26 
Stockholders' Equity
Kimberly-Clark Corporation
Preferred stock - no par value - authorized 20.0 million shares, none issued
 —  — 
Common stock - $1.25 par value - authorized 1.2 billion shares; issued 378.6 million shares at September 30, 2022 and December 31, 2021
 473  473 
Additional paid-in capital 633  605 
Common stock held in treasury, at cost - 41.1 and 41.8 million shares at September 30, 2022 and December 31, 2021, respectively
 (5,126) (5,183)
Retained earnings 8,086  7,858 
Accumulated other comprehensive income (loss) (3,629) (3,239)
Total Kimberly-Clark Corporation Stockholders' Equity 437  514 
Noncontrolling Interests 146  223 
Total Stockholders' Equity 583  737 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 17,836  $ 17,837 
See notes to the unaudited interim consolidated financial statements.
3

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited)


Three Months Ended September 30, 2022
(Millions of dollars, shares in thousands, except per share amounts) Common Stock
Issued		 Additional Paid-in Capital Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Non-controlling Interests Total Stockholders' Equity
Shares Amount Shares Amount
Balance at June 30, 2022 378,597  $ 473  $ 598  40,962  $ (5,111) $ 8,022  $ (3,389) $ 149  $ 742 
Net income in stockholders' equity, excludes redeemable interests' share —  —  —  —  —  467  —  9  476 
Other comprehensive income, net of tax,
excludes redeemable interests' share		 —  —  —  —  —  —  (239) (13) (252)
Stock-based awards exercised or vested —  —  (2) (84) 9  —  —  —  7 
Shares repurchased —  —  —  191  (25) —  —  —  (25)
Recognition of stock-based compensation —  —  31  —  —  —  —  —  31 
Dividends declared ($1.16 per share)
 —  —  —  —  —  (391) —  (1) (392)
Other —  —  6  —  1  (12) (1) 2  (4)
Balance at September 30, 2022 378,597  $ 473  $ 633  41,069  $ (5,126) $ 8,086  $ (3,629) $ 146  $ 583 


Nine Months Ended September 30, 2022
(Millions of dollars, shares in thousands, except per share amounts) Common Stock
Issued		 Additional Paid-in Capital Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Non-controlling Interests Total Stockholders' Equity
Shares Amount Shares Amount
Balance at December 31, 2021 378,597  $ 473  $ 605  41,762  $ (5,183) $ 7,858  $ (3,239) $ 223  $ 737 
Net income in stockholders' equity, excludes redeemable interests' share —  —  —  —  —  1,427  —  30  1,457 
Other comprehensive income, net of tax, excludes redeemable interests' share —  —  —  —  —  —  (389) (26) (415)
Stock-based awards exercised or vested —  —  (81) (1,272) 131  —  —  —  50 
Shares repurchased —  —  —  579  (75) —  —  —  (75)
Recognition of stock-based compensation —  —  98  —  —  —  —  —  98 
Dividends declared ($3.48 per share)
 —  —  —  —  —  (1,174) —  (82) (1,256)
Other —  —  11  —  1  (25) (1) 1  (13)
Balance at September 30, 2022 378,597  $ 473  $ 633  41,069  $ (5,126) $ 8,086  $ (3,629) $ 146  $ 583 
See notes to the unaudited interim consolidated financial statements.
4

Three Months Ended September 30, 2021
(Millions of dollars, shares in thousands, except per share amounts) Common Stock
Issued		 Additional Paid-in Capital Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Non-controlling Interests Total Stockholders' Equity
Shares Amount Shares Amount
Balance at June 30, 2021 378,597  $ 473  $ 627  41,661  $ (5,159) $ 7,798  $ (3,215) $ 234  $ 758 
Net income in stockholders' equity, excludes redeemable interests' share —  —  —  —  —  469  —  10  479 
Other comprehensive income, net of tax, excludes redeemable interests' share —  —  —  —  —  —  (89) (11) (100)
Stock-based awards exercised or vested —  —  (1) (237) 26  —  —  —  25 
Shares repurchased —  —  —  429  (58) —  —  —  (58)
Recognition of stock-based compensation —  —  (13) —  —  —  —  —  (13)
Dividends declared ($1.14 per share)
 —  —  —  —  —  (384) —  —  (384)
Other —  —  1  —  —  —  (1) —  — 
Balance at September 30, 2021 378,597  $ 473  $ 614  41,853  $ (5,191) $ 7,883  $ (3,305) $ 233  $ 707 

Nine Months Ended September 30, 2021
(Millions of dollars, shares in thousands, except per share amounts) Common Stock
Issued		 Additional Paid-in Capital Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Non-controlling Interests Total Stockholders' Equity
Shares Amount Shares Amount
Balance at December 31, 2020 378,597  $ 473  $ 657  39,873  $ (4,899) $ 7,567  $ (3,172) $ 243  $ 869 
Net income in stockholders' equity, excludes redeemable interests' share —  —  —  —  —  1,457  —  25  1,482 
Other comprehensive income, net of tax, excludes redeemable interests' share —  —  —  —  —  —  (132) (18) (150)
Stock-based awards exercised or vested —  —  (78) (1,189) 130  —  —  —  52 
Shares repurchased —  —  —  3,169  (422) —  —  —  (422)
Recognition of stock-based compensation —  —  28  —  —  —  —  —  28 
Dividends declared ($3.42 per share)
 —  —  —  —  —  (1,154) —  (17) (1,171)
Other —  —  7  —  —  13  (1) —  19 
Balance at September 30, 2021 378,597  $ 473  $ 614  41,853  $ (5,191) $ 7,883  $ (3,305) $ 233  $ 707 
5

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
CONSOLIDATED CASH FLOW STATEMENTS
(Unaudited)
Nine Months Ended
September 30
(Millions of dollars) 2022 2021
Operating Activities
Net income $ 1,446  $ 1,483 
Depreciation and amortization 568  572 
Asset impairments —  3 
Gain on previously held equity investment in Thinx (85) — 
Stock-based compensation 101  30 
Deferred income taxes (131) (42)
Net (gains) losses on asset dispositions 14  34 
Equity companies' earnings (in excess of) less than dividends paid (21) (25)
Operating working capital (166) (432)
Postretirement benefits 6  39 
Other 10  6 
Cash Provided by Operations 1,742  1,668 
Investing Activities
Capital spending (679) (734)
Acquisition of business, net of cash acquired (46) — 
Proceeds from dispositions of property 7  31 
Investments in time deposits (411) (632)
Maturities of time deposits 632  598 
Other (20) 1 
Cash Used for Investing (517) (736)
Financing Activities
Cash dividends paid (1,167) (1,133)
Change in short-term debt 487  854 
Debt proceeds —  5 
Debt repayments (312) (269)
Proceeds from exercise of stock options 84  52 
Acquisitions of common stock for the treasury (74) (393)
Cash dividends paid to noncontrolling interests (82) (17)
Other (45) (40)
Cash Used for Financing (1,109) (941)
Effect of Exchange Rate Changes on Cash and Cash Equivalents (24) (8)
Change in Cash and Cash Equivalents 92  (17)
Cash and Cash Equivalents - Beginning of Period 270  303 
Cash and Cash Equivalents - End of Period $ 362  $ 286 
See notes to the unaudited interim consolidated financial statements.

6


KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Accounting Policies
Basis of Presentation
The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted.
For further information, refer to the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2021. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries.
Highly Inflationary Accounting
GAAP guidance requires the use of highly inflationary accounting for countries whose cumulative three-year inflation exceeds 100 percent. Under highly inflationary accounting, the countries’ functional currency becomes the U.S. dollar, and its income statement and balance sheet are measured in U.S. dollars using both current and historical rates of exchange. In the second quarter of 2018, published inflation indices indicated that the three-year cumulative inflation in Argentina exceeded 100 percent, and as of July 1, 2018, we elected to adopt highly inflationary accounting for our subsidiaries in Argentina (“K-C Argentina”). The effect of changes in exchange rates on peso-denominated monetary assets and liabilities has been reflected in earnings in Other (income) and expense, net and was not material. As of September 30, 2022, K-C Argentina had a small net peso monetary position. Net sales of K-C Argentina were approximately 1 percent of our consolidated net sales for the nine months ended September 30, 2022 and 2021.
In the first quarter of 2022, published inflation indices indicated that the three-year cumulative inflation in Turkey exceeded 100 percent, and as of April 1, 2022, we elected to adopt highly inflationary accounting for our subsidiary in Turkey (“K-C Turkey”). The effect of changes in exchange rates on lira-denominated monetary assets and liabilities has been reflected in earnings in Other (income) and expense, net and was not material. As of September 30, 2022, K-C Turkey had a small net lira monetary position. Net sales of K-C Turkey were less than 1 percent of our consolidated net sales for the nine months ended September 30, 2022.
Recently Issued Accounting Standard
In September 2022, the Financial Accounting Standards Board issued Accounting Standard Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The new guidance requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of the financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the provision on roll forward information, which is effective for fiscal years beginning after December 15, 2023. As the guidance requires only additional disclosures, the effects of this standard on our financial position, results of operations and cash flows are not expected to be material.
Note 2. 2022 Acquisition
On February 24, 2022, we completed our acquisition of a majority and controlling share of Thinx Inc. (“Thinx”), an industry leader in the reusable period and incontinence underwear category, for total consideration of $181 consisting of cash of $53, the fair value of our previously held equity investment of $127, and certain share-based award costs of $1.
We previously accounted for our ownership interest in Thinx as an equity method investment, but upon increasing our ownership to 58%, we began consolidating the operations of Thinx into our financial statements at the end of the first quarter of 2022. The consolidated results of operations for Thinx are reported in our Personal Care business segment on a one-month lag. The share of Thinx net income and equity attributable to the third-party minority owner of Thinx is classified in our consolidated income statement within Net income attributable to noncontrolling interests and in our consolidated balance sheet within Redeemable Common and Preferred Securities of Subsidiaries. This noncontrolling equity interest is measured at the estimated redemption value, which approximates fair value.
7

We have substantially completed an initial purchase price allocation in which we utilized several generally accepted valuation methodologies to estimate the fair value of certain acquired assets. The primary valuation methods included two forms of the Income Approach (i.e., the multi-period excess earnings method [distributor method] and the relief-from-royalty method). These valuation methodologies are commonly used to value similar identifiable intangible assets in the Consumer Packaged Goods industry. All of the selected valuation methodologies incorporate unobservable inputs, or Level 3 inputs, as defined by the fair value hierarchy in Accounting Standard Codification 820, Fair Value Measurements. In connection with these valuation methodologies, we are required to make estimates and assumptions regarding market comparable companies, revenue growth rates, operating margins, distributor and customer attrition rates, royalty rates, distributor margins, discount rates, etc., which are primarily based on cash flow forecasts, business plans, economic projections and other information available to market participants.
The total purchase price consideration was allocated to the net assets acquired based upon their respective estimated fair values as follows:
Current Assets $ 28 
Property, Plant and Equipment, Net 2 
Goodwill 297 
Other Intangible Assets, Net 123 
Other Assets 4 
Current Liabilities (17)
Deferred Income Taxes (18)
Other Liabilities (4)
Fair value of net assets acquired 415 
Less fair value of non-controlling interest (234)
Total purchase price consideration $ 181 
Other Intangible Assets, Net includes brands and customer relationships which have estimated useful lives of 4 to 15 years, primarily 15 years. Based on the carrying value of these finite-lived assets as of September 30, 2022, amortization expense per year for each of the next five years is estimated to be approximately $8.
Goodwill of $297 was allocated to the Personal Care business segment. The goodwill is primarily attributable to future growth opportunities and any intangible assets that did not qualify for separate recognition. For tax purposes, the acquisition of additional Thinx shares was treated as a stock acquisition, and the goodwill acquired is not tax deductible.
The preliminary estimates of the fair value of identifiable assets acquired and liabilities assumed are subject to revisions, which may result in adjustments to the preliminary values discussed above. We continue to evaluate potential contingencies that may have existed as of the acquisition date and expect to finalize the purchase price allocation no later than the first quarter of 2023.
As a result of this transaction during the quarter ended March 31, 2022, an $85 non-recurring, non-cash gain was recognized in Other (income) expense, net as a result of the remeasurement of the carrying value of our previously held equity investment to fair value, and related transaction and integration costs of $21 were recorded in Marketing, research and general expenses. This recognition resulted in a net benefit of $64 pre-tax ($68 after tax) being included in our consolidated income statement for the quarter ended March 31, 2022. In addition, we removed the non-cash gain impact from Operating Activities in our consolidated cash flow statements for the nine months ended September 30, 2022.
Pro forma results of operations have not been presented as the impact on our consolidated financial statements is not material.
8

Note 3. Fair Value Information
The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:
Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.
Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.
Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable.
A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
During the nine months ended September 30, 2022 and for the full year 2021, there were no significant transfers to or from level 3 fair value determinations.
Derivative assets and liabilities are measured on a recurring basis at fair value. At September 30, 2022 and December 31, 2021, derivative assets were $283 and $65, respectively, and derivative liabilities were $131 and $41, respectively. The fair values of derivatives used to manage interest rate risk and commodity price risk are based on LIBOR rates and interest rate swap curves and commodity price quotations, respectively. The fair values of hedging instruments used to manage foreign currency risk are based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. Measurement of our derivative assets and liabilities is considered a level 2 measurement. Additional information on our classification and use of derivative instruments is contained in Note 6.
Redeemable common and preferred securities of subsidiaries are measured on a recurring basis at their estimated redemption values, which approximate fair value. As of September 30, 2022 and December 31, 2021, the securities were valued at $260 and $26, respectively. No redeemable common securities were outstanding at December 31, 2021. The securities are not traded in active markets, and their measurement is considered a level 3 measurement.
Company-owned life insurance ("COLI") assets are measured on a recurring basis at fair value. COLI assets were $63 and $72 at September 30, 2022 and December 31, 2021, respectively. The COLI policies are a source of funding primarily for our nonqualified employee benefits and are included in Other Assets. The COLI policies are measured at fair value using the net asset value per share practical expedient, and therefore, are not classified in the fair value hierarchy.
The following table includes the fair value of our financial instruments for which disclosure of fair value is required:
Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value
September 30, 2022 December 31, 2021
Assets
Cash and cash equivalents(a)
 1 $ 362  $ 362  $ 270  $ 270 
Time deposits(b)
 1 168  168  416  416 
Liabilities
Short-term debt(c)
 2 599  599  118  118 
Long-term debt(d)
 2 7,988  7,269  8,456  9,492 
(a)Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.
(b)Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in Other current assets or Other Assets in the consolidated balance sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.
(c)Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
(d)Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.
9

Note 4. Earnings Per Share ("EPS")
There are no adjustments required to be made to net income for purposes of computing EPS. The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows:
Three Months Ended
September 30		 Nine Months Ended
September 30
(Millions of shares) 2022 2021 2022 2021
Basic 337.6  336.8  337.3  337.4 
Dilutive effect of stock options and restricted share unit awards 0.7  0.7  1.0  1.0 
Diluted 338.3  337.5  338.3  338.4 
The impact of options outstanding that were not included in the computation of diluted EPS because their exercise price was greater than the average market price of the common shares was insignificant. The number of common shares outstanding as of September 30, 2022 and 2021 was 337.5 million and 336.7 million, respectively.
Note 5. Stockholders' Equity
Net unrealized currency gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries, except those in highly inflationary economies, are recorded in Accumulated Other Comprehensive Income ("AOCI"). For these operations, changes in exchange rates generally do not affect cash flows; therefore, unrealized translation adjustments are recorded in AOCI rather than net income. Upon sale or substantially complete liquidation of any of these subsidiaries, the applicable unrealized translation would be removed from AOCI and reported as part of the gain or loss on the sale or liquidation.
Also included in unrealized translation amounts are the effects of foreign exchange rate changes on intercompany balances of a long-term investment nature and transactions designated as hedges of net foreign investments.
The change in net unrealized currency translation for the nine months ended September 30, 2022 was primarily due to the weakening of certain foreign currencies versus the U.S. dollar.
The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows:
Unrealized Translation Defined Benefit Pension Plans Other Postretirement Benefit Plans Cash Flow Hedges and Other
Balance as of December 31, 2020 $ (2,157) $ (912) $ (40) $ (63)
Other comprehensive income (loss) before reclassifications
 (266) 5  (12) 56 
(Income) loss reclassified from AOCI —  52  (a) (3) (a) 35 
Net current period other comprehensive income (loss) (266) 57  (15) 91 
Balance as of September 30, 2021 $ (2,423) $ (855) $ (55) $ 28 
Balance as of December 31, 2021 $ (2,422) $ (803) $ (34) $ 20 
Other comprehensive income (loss) before
    reclassifications		 (501) (6) (2) 101 
(Income) loss reclassified from AOCI —  44  (a) —  (a) (26)
Net current period other comprehensive income (loss) (501) 38  (2) 75 
Balance as of September 30, 2022 $ (2,923) $ (765) $ (36) $ 95 
(a) Included in computation of net periodic benefit costs.
Note 6. Objectives and Strategies for Using Derivatives
As a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest rates, and commodity prices. We employ a number of practices to manage these risks, including operating and financing activities and, where appropriate, the use of derivative instruments.
At September 30, 2022 and December 31, 2021, derivative assets were $283 and $65, respectively, and derivative liabilities were $131 and $41, respectively, primarily comprised of foreign currency exchange contracts. Derivative assets are recorded in
10

Other current assets or Other Assets, as appropriate, and derivative liabilities are recorded in Accrued expenses and other current liabilities or Other Liabilities, as appropriate.
Foreign Currency Exchange Rate Risk
Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowings. A portion of our balance sheet translation exposure for certain affiliates, which results from changes in translation rates between the affiliates’ functional currencies and the U.S. dollar, is hedged with cross-currency swap contracts and certain foreign denominated debt which are designated as net investment hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged with primarily undesignated derivative instruments.
Derivative instruments are entered into to hedge a portion of forecasted cash flows denominated in foreign currencies for non-U.S. operations' purchases of raw materials, which are priced in U.S. dollars, and imports of intercompany finished goods and work-in-process priced predominantly in U.S. dollars and euros. The derivative instruments used to manage these exposures are designated as cash flow hedges.
Interest Rate Risk
Interest rate risk is managed using a portfolio of variable and fixed-rate debt composed of short and long-term instruments. Interest rate swap contracts may be used to facilitate the maintenance of the desired ratio of variable and fixed-rate debt and are designated as fair value hedges. From time to time, we also hedge the anticipated issuance of fixed-rate debt, and these contracts are designated as cash flow hedges.
Commodity Price Risk
We use derivative instruments, such as forward contracts, to hedge a limited portion of our exposure to market risk arising from changes in prices of certain commodities. These derivatives are designated as cash flow hedges of specific quantities of the underlying commodity expected to be purchased in future months. In addition, we utilize negotiated contracts of varying durations along with strategic pricing mechanisms to manage volatility for a portion of our commodity costs.
Fair Value Hedges
Derivative instruments that are designated and qualify as fair value hedges are predominantly used to manage interest rate risk. The fair values of these interest rate derivative instruments are recorded as an asset or liability, as appropriate, with the offset recorded in Interest expense. The offset to the change in fair values of the related debt is also recorded in Interest expense. Any realized gain or loss on the derivatives that hedge interest rate risk is amortized to Interest expense over the life of the related debt. As of September 30, 2022, the aggregate notional values and carrying values of debt subject to outstanding interest rate contracts designated as fair value hedges were $525 and $465, respectively. For the nine months ended September 30, 2022 and 2021, gains or losses recognized in Interest expense for interest rate swaps were not significant.
Cash Flow Hedges
For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same income statement line and period that the hedged exposure affects earnings. As of September 30, 2022, outstanding commodity forward contracts were in place to hedge a limited portion of our estimated requirements of the related underlying commodities in the remainder of 2022 and future periods. During 2022, we increased the notional level of our foreign currency designated cash flow hedges to help mitigate the impacts of significantly increased macroeconomic foreign currency rate fluctuations, and as of September 30, 2022, the aggregate notional value of outstanding foreign exchange derivative contracts designated as cash flow hedges was $2,106. For the nine months ended September 30, 2022 and 2021, no significant gains or losses were reclassified into Interest expense, Cost of products sold or Other (income) and expense, net as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At September 30, 2022, amounts to be reclassified from AOCI into Interest expense, Cost of products sold or Other (income) and expense, net during the next twelve months are not expected to be material. The maximum maturity of cash flow hedges in place at September 30, 2022 is September 2025.
Net Investment Hedges
For derivative instruments that are designated and qualify as net investment hedges, the aggregate notional value was $1.3 billion at September 30, 2022. We exclude the interest accruals on cross-currency swap contracts and the forward points on foreign exchange forward contracts from the assessment and measurement of hedge effectiveness.  We recognize the interest accruals on cross-currency swap contracts in earnings within Interest expense.  We amortize the forward points on foreign exchange contracts into earnings within Interest expense over the life of the hedging relationship.  Changes in fair value of net investment hedges are recorded in AOCI and offset the change in the value of the net investment being hedged.  For the nine
11

months ended September 30, 2022, unrealized gains of $176 related to net investment hedge fair value changes were recorded in AOCI and no significant amounts were reclassified from AOCI to Interest expense.
No significant amounts were excluded from the assessment of net investment, fair value or cash flow hedge effectiveness as of September 30, 2022.
Undesignated Hedging Instruments
Gains or losses on undesignated foreign exchange hedging instruments are immediately recognized in Other (income) and expense, net. Losses of $13 and $2 were recorded in the three months ended September 30, 2022 and 2021, respectively. Losses of $48 and $8 were recorded in the nine months ended September 30, 2022 and 2021, respectively. The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. At September 30, 2022, the notional value of these undesignated derivative instruments was approximately $2.1 billion.
Note 7. Business Segment Information
We are organized into operating segments based on product groupings. These operating segments have been aggregated into three reportable global business segments: Personal Care, Consumer Tissue and K-C Professional. The reportable segments were determined in accordance with how our chief operating decision maker and our executive managers develop and execute global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. Segment management is evaluated on several factors, including operating profit. Segment operating profit excludes Other (income) and expense, net and income and expense not associated with ongoing operations of the business segments, including the costs of corporate decisions related to the 2018 Global Restructuring Program which was completed in 2021.
The principal sources of revenue in each global business segment are described below:
•Personal Care brands offer our consumers a trusted partner in caring for themselves and their families by delivering confidence, protection and discretion through a wide variety of innovative solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products.  Products in this segment are sold under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Depend, Plenitud, Softex, Poise and other brand names.
•Consumer Tissue offers a wide variety of innovative solutions and trusted brands that responsibly improve everyday living for families around the world.  Products in this segment include facial and bathroom tissue, paper towels, napkins and related products, and are sold under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve and other brand names.
•K-C Professional partners with businesses to create Exceptional Workplaces, helping to make them healthier, safer and more productive through a range of solutions and supporting products such as wipers, tissue, towels, apparel, soaps and sanitizers. Our brands, including Kleenex, Scott, WypAll, Kimtech and KleenGuard are well known for quality and trusted to help people around the world work better.
12

Information concerning consolidated operations by business segment is presented in the following tables:
Three Months Ended September 30 Nine Months Ended September 30
2022 2021 Change 2022 2021 Change
NET SALES
Personal Care $ 2,628  $ 2,656  -1  % $ 8,067  $ 7,635  +6  %
Consumer Tissue 1,578  1,541  +2  % 4,683  4,475  +5  %
K-C Professional 836  797  +5  % 2,418  2,314  +4  %
Corporate & Other 11  16  N.M. 43  51  N.M.
TOTAL NET SALES $ 5,053  $ 5,010  +1  % $ 15,211  $ 14,475  +5  %
OPERATING PROFIT
Personal Care $ 423  $ 496  -15  % $ 1,364  $ 1,431  -5  %
Consumer Tissue 218  222  -2  % 567  687  -17  %
K-C Professional 119  96  +24  % 294  332  -11  %
Corporate & Other(a)
 (90) (150) N.M. (298) (386) N.M.
Other (income) and expense, net(a)
 15  7  +114  % (42) 24  N.M.
TOTAL OPERATING PROFIT $ 655  $ 657  —  $ 1,969  $ 2,040  -3  %
(a)    Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including the non-cash, non-recurring gain and transaction and integration costs related to the acquisition of a controlling interest in Thinx in 2022 and charges related to the 2018 Global Restructuring Program in 2021. Restructuring charges related to the Personal Care, Consumer Tissue and K-C Professional for the three months ended September 30, 2021 were, $32, $42, and $10, respectively and for the nine months ended September 30, 2021 were $71, $84 and $19, respectively.
N.M. - Not Meaningful
Sales of Principal Products:
Three Months Ended September 30 Nine Months Ended September 30
(Billions of dollars) 2022 2021 2022 2021
Baby and child care products $ 1.7  $ 1.8  $ 5.5  $ 5.3 
Consumer tissue products 1.6  1.5  4.7  4.5 
Away-from-home professional products 0.8  0.8  2.4  2.3 
All other 1.0  0.9  2.6  2.4 
Consolidated $ 5.1  $ 5.0  $ 15.2  $ 14.5 
Note 8. Supplemental Balance Sheet Data
The following schedule presents a summary of inventories by major class:
September 30, 2022 December 31, 2021
LIFO Non-LIFO Total LIFO Non-LIFO Total
Raw materials $ 167  $ 382  $ 549  $ 141  $ 352  $ 493 
Work in process 148  105  253  153  89  242 
Finished goods 613  815  1,428  607  835  1,442 
Supplies and other —  292  292  —  280  280 
928  1,594  2,522  901  1,556  2,457 
Excess of FIFO or weighted-average cost over
  LIFO cost		 (241) —  (241) (218) —  (218)
Total $ 687  $ 1,594  $ 2,281  $ 683  $ 1,556  $ 2,239 
Inventories are valued at the lower of cost or net realizable value, determined on the FIFO or weighted-average cost methods, and at the lower of cost or market, determined on the LIFO cost method.
13

The following schedule presents a summary of property, plant and equipment, net:
September 30, 2022 December 31, 2021
Land $ 153  $ 169 
Buildings 2,972  2,993 
Machinery and equipment 14,372  14,606 
Construction in progress 647  760 
18,144  18,528 
Less accumulated depreciation (10,407) (10,431)
Total $ 7,737  $ 8,097 

14

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations
Introduction
This management's discussion and analysis ("MD&A") of financial condition and results of operations is intended to provide investors with an understanding of our recent performance, financial condition and prospects.  Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted. The following will be discussed and analyzed:
•Overview of Third Quarter 2022 Results
•Results of Operations and Related Information
•Liquidity and Capital Resources
•Information Concerning Forward-Looking Statements
We describe our business outside North America in two groups – Developing and Emerging Markets ("D&E") and Developed Markets. D&E markets comprise Eastern Europe, the Middle East and Africa, Latin America and Asia-Pacific, excluding Australia and South Korea. Developed Markets consist of Western and Central Europe, Australia and South Korea. We have three reportable business segments: Personal Care, Consumer Tissue and K-C Professional. These business segments are described in greater detail in Note 7 to the unaudited interim consolidated financial statements.
On February 24, 2022, we completed our acquisition of a majority and controlling share of Thinx Inc. (“Thinx”), an industry leader in the reusable period and incontinence underwear category, for total consideration of $181 consisting of cash of $53, the fair value of our previously held equity investment of $127, and certain share-based award costs of $1.
This section presents a discussion and analysis of our third quarter 2022 net sales, operating profit and other information relevant to an understanding of the results of operations. In addition, we provide commentary regarding organic sales growth, which describes the impact of changes in volume, net selling prices and product mix on net sales. Change in foreign currency exchange rates, acquisitions and exited businesses also impact the year-over-year change in net sales. Our analysis compares the three and nine months ended September 30, 2022 results to the same periods in 2021.
In March 2022, we implemented significant adjustments to our business in Russia and suspended substantially all media, advertising and promotional activity as well as capital investments in our sole manufacturing facility. Consistent with the humanitarian nature of our products, we are manufacturing and selling only essential items, such as baby diapers and feminine pads, which are critical to the health and hygiene of women, girls and babies, but our ability to manufacture these items may change as the situation evolves. Our Russia business has historically represented approximately 1 to 2 percent of our net sales, operating profit and total assets. We are actively monitoring the situation, and as the business, geopolitical and regulatory environment concerning Russia evolves, our assets may be partially or fully impaired. We are also monitoring the increased risk of cyber-based attacks as a result of the Russian invasion of Ukraine and have implemented heightened cyber-security monitoring of our systems designed to address the evolving threat landscape. We are experiencing increased input costs as a result of inflation and supply chain complexities related to the Russian invasion that are having a negative impact on our operations. For a more complete discussion of the risks we encounter in our business, please refer to Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021.
Throughout this MD&A, we refer to financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures. These measures include adjusted gross and operating profit, adjusted net income, adjusted earnings per share and adjusted effective tax rate. We believe these measures provide our investors with additional information about our underlying results and trends, as well as insight into some of the financial measures used to evaluate management.
Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures, and they should be read only in conjunction with our unaudited interim consolidated financial statements prepared in accordance with GAAP.  There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded.  We compensate for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures.
The non-GAAP financial measures exclude the following items for the relevant time periods as indicated in the reconciliations included later in this MD&A:
15

•Pension settlements - In 2022, pension settlement charges were recognized related to lump-sum distributions from pension plan assets exceeding the total of annual service and interest costs resulting in a recognition of deferred actuarial losses.
•Acquisition of controlling interest in Thinx – In the first quarter of 2022, we increased our investment in Thinx. As a result of this transaction, a net benefit was recognized primarily due to the non-recurring, non-cash gain recognized related to the remeasurement of the carrying value of our previously held equity investment to fair value partially offset by transaction and integration costs. See Item 1, Note 2 to the unaudited interim consolidated financial statements for details.
The non-GAAP financial measures also exclude charges in 2021 for the 2018 Global Restructuring Program as indicated in the reconciliations included later in this MD&A. In 2018, we initiated this restructuring in order to reduce our structural cost base by streamlining and simplifying our manufacturing supply chain and overhead organization. As a result, we recognized restructuring charges in 2018, 2019, 2020 and 2021 for this program. Restructuring actions were completed in 2021.
Overview of Third Quarter 2022 Results
•Net sales of $5.1 billion increased 1 percent compared to the year-ago period, including organic sales growth of 5 percent.
•Operating profit was $655 in 2022 and $657 in 2021. Net Income Attributable to Kimberly-Clark Corporation was $467 in 2022 compared to $469 in 2021, and diluted earnings per share were $1.38 in 2022 compared to $1.39 in 2021. Results in 2022 include pension settlement charges, compared to 2021 results, which include charges related to the 2018 Global Restructuring Program.
Results of Operations and Related Information
This section presents a discussion and analysis of our third quarter 2022 net sales, operating profit and other information relevant to an understanding of the results of operations.
Consolidated
Selected Financial Results Three Months Ended September 30 Nine Months Ended September 30
2022 2021 Percent Change 2022 2021 Percent Change
Net Sales:
North America $ 2,682  $ 2,692  —  $ 7,953  $ 7,436  +7  %
Outside North America 2,446  2,399  +2  % 7,471  7,274  +3  %
Intergeographic sales (75) (81) -7  % (213) (235) -9  %
Total Net Sales 5,053  5,010  +1  % 15,211  14,475  +5  %
Operating Profit:
North America 519  564  -8  % 1,475  1,561  -6  %
Outside North America 241  250  -4  % 750  889  -16  %
Corporate & Other(a)
 (90) (150) N.M. (298) (386) N.M.
Other (income) and expense, net(a)
 15  7  +114  % (42) 24  N.M.
Total Operating Profit 655  657  —  1,969  2,040  -3  %
Share of net income of equity companies 29  21  +38  % 81  88  -8  %
Net Income Attributable to Kimberly-Clark Corporation
 467  469  —  1,427  1,457  -2  %
Diluted Earnings per Share 1.38  1.39  -1  % 4.22  4.31  -2  %
(a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including adjustments as indicated in the Non-GAAP Reconciliations.
N.M. - Not Meaningful
16

GAAP to Non-GAAP Reconciliations of Selected Financial Results
Three Months Ended September 30, 2022
As
Reported		 Pension Settlements As
Adjusted
Non-GAAP
Nonoperating expense $ (18) $ (10) $ (8)
Provision for income taxes (127) 2  (129)
Effective tax rate 22.4  % — 22.3  %
Net Income Attributable to Kimberly-Clark Corporation 467  (8) 475 
Diluted Earnings per Share(a)
 1.38  (0.02) 1.40 
Three Months Ended September 30, 2021
As
Reported		 2018 Global
Restructuring
Program		 As
Adjusted
Non-GAAP
Cost of products sold $ 3,527  $ 48  $ 3,479 
Gross Profit 1,483  (48) 1,531 
Marketing, research and general expenses 819  39  780 
Other (income) and expense, net 7  1  6 
Operating Profit 657  (88) 745 
Nonoperating expense (10) (9) (1)
Provision for income taxes (126) 16  (142)
Effective tax rate 21.6  % — 20.9  %
Net income attributable to noncontrolling interests (10) 2  (12)
Net Income Attributable to Kimberly-Clark Corporation 469  (79) 548 
Diluted Earnings per Share(a)
 1.39  (0.23) 1.62 

Nine Months Ended September 30, 2022
As
Reported		  Acquisition of Controlling Interest in Thinx Pension Settlements As
Adjusted
Non-GAAP
Marketing, research and general expenses $ 2,665  $ 21  $ —  $ 2,644 
Other (income) and expense, net (42) (85) —  43 
Operating Profit 1,969  64  —  1,905 
Nonoperating expense (49) —  (34) (15)
Provision for income taxes (356) 4  8  (368)
Effective tax rate 20.7  % — —  21.8  %
Net Income Attributable to Kimberly-Clark Corporation 1,427  68  (26) 1,385 
Diluted Earnings per Share(a)
 4.22  0.20  (0.08) 4.09 

17

Nine Months Ended September 30, 2021
As
Reported		 2018 Global
Restructuring
Program		 As
Adjusted
Non-GAAP
Cost of products sold $ 9,923  $ 98  $ 9,825 
Gross Profit 4,552  (98) 4,650 
Marketing, research and general expenses 2,488  78  2,410 
Other (income) and expense, net 24  9  15 
Operating Profit 2,040  (185) 2,225 
Nonoperating expense (71) (65) (6)
Provision for income taxes (386) 48  (434)
Effective tax rate 21.7  % — 21.4  %
Net income attributable to noncontrolling interests (26) 3  (29)
Net Income Attributable to Kimberly-Clark Corporation 1,457  (199) 1,656 
Diluted Earnings per Share(a)
 4.31  (0.59) 4.89 
(a) "As Adjusted Non-GAAP" may not equal "As Reported" plus "Adjustments" as a result of rounding.
Analysis of Consolidated Results
Net Sales Percent Change Adjusted Operating Profit Percent Change
Three Months Ended
September 30		 Nine Months Ended September 30 Three Months Ended September 30 Nine Months Ended September 30
Volume (5) (1) Volume (13) (7)
Net Price 9  8  Net Price 63  52 
Mix/Other 1  1  Input Costs (48) (55)
Currency (4) (3)
Cost Savings(c)
 11  8 
Total(a)
 1  5  Currency Translation (2) (2)
Other(d)
 (23) (10)
Organic(b)
 5  8  Total (12) (14)
(a) Total may not equal the sum of volume, net price, mix/other and currency due to rounding.
(b) Combined impact of changes in volume, net price and mix/other.
(c) Benefits of the FORCE (Focused On Reducing Costs Everywhere) program.
(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.
Net sales in the third quarter of $5.1 billion increased 1 percent compared to the year-ago period. Organic sales increased 5 percent as changes in net selling prices and product mix increased sales by 9 percent and 1 percent, respectively, while volumes declined 5 percent. Changes in foreign currency exchange rates reduced sales by 4 percent.
In North America, organic sales decreased 2 percent in consumer products and increased 5 percent in K-C Professional. Outside North America, organic sales rose 11 percent in both D&E and developed markets.
Operating profit in the third quarter was $655 in 2022 and $657 in 2021. Excluding the charges related to the 2018 Global Restructuring Program, 2021 adjusted operating profit was $745. Results were impacted by $360 of higher input costs, lower volumes, higher marketing, research and general expense as well as unfavorable foreign currency effects. Results benefited from higher net selling prices and $80 of cost savings from our FORCE program.
The third quarter effective tax rate was 22.4 percent in 2022 and 21.6 percent in 2021. The third quarter adjusted effective tax was 22.3 percent in 2022 and 20.9 percent in 2021.
Our share of net income of equity companies in the third quarter was $29 in 2022 and $21 in 2021.
Diluted net income per share for the third quarter was $1.38 in 2022 and $1.39 in 2021. Third quarter adjusted earnings per share were $1.40 in 2022, a decrease of 14 percent compared to $1.62 in 2021.
18

Year-to-date net sales of $15.2 billion increased 5 percent compared to the year ago period. Organic sales increased 8 percent, as changes in net selling prices and product mix increased sales by 8 percent and 1 percent, respectively, and volumes declined 1 percent. Changes in foreign currency exchange rates decreased sales by 3 percent. Year-to-date operating profit was $1,969 in 2022 and $2,040 in 2021. Results in 2022 include the net benefit of the acquisition of a controlling interest of Thinx, and results in 2021 include charges related to the 2018 Global Restructuring Program. Year-to-date adjusted operating profit was $1,905 in 2022 and $2,225 in 2021. Results were impacted by over $1.2 billion of higher input costs, higher marketing, research and general spending and unfavorable foreign currency effects. Results benefited from organic sales growth, $175 of FORCE savings and lower other manufacturing costs.
Through nine months, diluted net income per share was $4.22 in 2022 and $4.31 in 2021. Year-to-date adjusted earnings per share were $4.09 in 2022, a decrease of 16 percent compared to $4.89 in 2021.
Results by Business Segments
Personal Care
Three Months Ended September 30 Nine Months Ended September 30


Three Months Ended September 30 Nine Months Ended September 30
2022 2021 2022 2021 2022 2021 2022 2021
Net Sales $ 2,628  $ 2,656  $ 8,067  $ 7,635  Operating Profit $ 423  $ 496  $ 1,364  $ 1,431 
Net Sales Percent Change Percent Change Operating Profit Percent Change Percent Change
Volume (7) (2) Volume (14) (5)
Net Price 8  8  Net Price 44  45 
Mix/Other 1  2  Input Costs (29) (37)
Acquisition/Exited
   Businesses(e)
 1  — 
Cost Savings(c)
 7  6 
Currency (4) (3) Currency Translation (2) (3)
Total(a)
 (1) 6 
Other(d)
 (21) (11)
Organic(b)
 2  8  Total (15) (5)
(a) Total may not equal the sum of volume, net price, mix/other and currency due to rounding.
(b) Combined impact of changes in volume, net price and mix/other.
(c) Benefits of the FORCE program.
(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.
(e) Combined impact of the acquisition of Thinx Inc. and exited businesses in conjunction with the 2018 Global Restructuring Program.
Third quarter net sales in North America decreased 5 percent. Volumes declined 10 percent, while changes in net selling prices increased sales by 4 percent and the Thinx acquisition increased sales by approximately 2 percent. The volume comparison reflects elevated shipments in the year ago period to restore retailer inventory levels following supply disruptions. The planned exit of a private label contract earlier this year as well as some reductions in retailer inventory levels late in the quarter also impacted the comparison.
Net sales in D&E markets increased 5 percent. Changes in net selling prices and product mix increased sales by 15 percent and 3 percent, respectively, while volumes declined 6 percent. Changes in foreign currency exchange rates decreased sales by 6 percent. Organic sales growth was strong across Latin America and the Asia Pacific region.
Net sales in developed markets outside North America decreased 4 percent. Changes in foreign currency exchange rates reduced sales by 12 percent. Changes in net selling prices increased sales by 5 percent and volumes grew 3 percent.
Operating profit of $423 decreased 15 percent. The comparison was impacted by input cost inflation, lower volumes and associated fixed cost under absorption, higher marketing, research and general spending as well as unfavorable foreign currency effects. Results benefited from higher net selling prices and cost savings.
19

Consumer Tissue
Three Months Ended September 30 Nine Months Ended September 30


Three Months Ended September 30 Nine Months Ended September 30
2022 2021 2022 2021 2022 2021 2022 2021
Net Sales $ 1,578  $ 1,541  $ 4,683  $ 4,475  Operating Profit $ 218  $ 222  $ 567  $ 687 
Net Sales Percent Change Percent Change Operating Profit Percent Change Percent Change
Volume (3) 1  Volume (7) (3)
Net Price 9  7  Net Price 63  46 
Mix/Other —  —  Input Costs (62) (69)
Currency (4) (3)
Cost Savings(c)
 11  8 
Total(a)
 2  5  Currency Translation (1) (1)
Other(d)
 (6) 2 
Organic(b)
 7  8  Total (2) (17)
(a) Total may not equal the sum of volume, net price, mix/other and currency due to rounding.
(b) Combined impact of changes in volume, net price and mix/other.
(c) Benefits of the FORCE program.
(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.
Third quarter net sales in North America increased 5 percent. Changes in net selling prices increased sales by 7 percent, while volumes declined 2 percent. Higher net selling prices were achieved across all sub-segments while volume decline was primarily in bathroom tissue.
Net sales in D&E markets increased 3 percent. Changes in net selling prices and product mix increased sales by 12 percent and 1 percent, respectively, while volumes declined 6 percent. Changes in foreign currency exchange rates decreased sales by 5 percent.
Net sales in developed markets outside North America decreased 2 percent. Changes in foreign currency exchange rates decreased sales by 13 percent. Changes in net selling prices increased sales by approximately 12 percent, while volumes declined 1 percent.
Operating profit of $218 decreased 2 percent. The comparison was impacted by input cost inflation, higher marketing, research and general spending, and unfavorable foreign currency effects. Results benefited from organic sales growth, cost savings and lower other manufacturing costs.
K-C Professional
Three Months Ended September 30 Nine Months Ended September 30


Three Months Ended September 30 Nine Months Ended September 30
2022 2021 2022 2021 2022 2021 2022 2021
Net Sales $ 836  $ 797  $ 2,418  $ 2,314  Operating Profit $ 119  $ 96  $ 294  $ 332 
Net Sales Percent Change Percent Change Operating Profit Percent Change Percent Change
Volume (5) (3) Volume (14) (16)
Net Price 14  9  Net Price 113  63 
Mix/Other 1  1  Input Costs (77) (68)
Currency (4) (3)
Cost Savings(c)
 21  11 
Total(a)
 5  4  Currency Translation (5) (2)
Other(d)
 (14) 1 
Organic(b)
 9  7  Total 24  (11)
(a) Total may not equal the sum of volume, net price, mix/other and currency due to rounding.
(b) Combined impact of changes in volume, net price and mix/other.
(c) Benefits of the FORCE program.
(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.
20

Third quarter net sales in North America increased 5 percent. Changes in net selling prices and product mix increased sales by 14 percent and approximately 1 percent, respectively, while volumes declined 9 percent. Washroom products sales were up double-digits while sales of safety products decreased versus a strong year-ago.
Net sales in D&E markets increased 7 percent. Changes in net selling prices increased sales by 8 percent, volumes grew 2 percent, and changes in product mix increased sales by approximately 2 percent. Changes in foreign currency exchange rates decreased sales by 6 percent.
Net sales in developed markets outside North America increased 5 percent. Changes in net selling prices and product mix increased sales by 19 percent and 1 percent, respectively. Changes in foreign currency exchange rates decreased sales by 15 percent.
Operating profit of $119 increased 24 percent. Results benefited from higher net selling prices and cost savings. The comparison was impacted by input cost inflation, lower volumes and unfavorable foreign currency effects.
Liquidity and Capital Resources
Cash Provided by Operations
Cash provided by operations was $1.7 billion for the first nine months of 2022, consistent with the prior year.
Investing
During the nine months ended September 30, 2022, our capital spending was $679 compared to $734 in the prior year. We now anticipate that full year capital spending will be $0.9 billion to $1.0 billion. Acquisition of business, net of cash acquired of $46 in the first nine months of 2022 reflected the acquisition of a controlling interest of Thinx.
Financing
Our short-term debt, which consists of U.S. commercial paper with original maturities up to 90 days and/or other similar short-term debt issued by non-U.S. subsidiaries, was $0.6 billion as of September 30, 2022 (included in Debt payable within one year on the consolidated balance sheet). The average month-end balance of short-term debt for the third quarter of 2022 was $0.7 billion. These short-term borrowings provide supplemental funding to support our operations. The level of short-term debt generally fluctuates depending upon the amount of operating cash flows and the timing of customer receipts and payments for items such as dividends and income taxes.
At September 30, 2022 and December 31, 2021, total debt was $8.6 billion.
We maintain a $2.0 billion revolving credit facility which expires in June 2026 and a $775 revolving credit facility which expires in June 2023.  These facilities, currently unused, support our commercial paper program and would provide liquidity in the event our access to the commercial paper markets is unavailable for any reason.
The United Kingdom’s Financial Conduct Authority, which regulates the London Interbank Offered Rate (“LIBOR”), is in the process of phasing out LIBOR with completion of the phase out expected by June 30, 2023. We have evaluated the potential effect of the elimination of LIBOR and do not expect the effect to be material. Accounting guidance has been issued to ease the transition to alternative reference rates from a financial reporting perspective.
We repurchase shares of Kimberly-Clark common stock from time to time pursuant to publicly announced share repurchase programs. During the first nine months of 2022, we repurchased 579 thousand shares of our common stock at a cost of $75 through a broker in the open market. We are targeting full-year 2022 share repurchases of approximately $100, subject to market conditions.
We believe that our ability to generate cash from operations and our capacity to issue short-term and long-term debt are adequate to fund working capital, capital spending, pension contributions, dividends and other needs for the foreseeable future. Further, we do not expect restrictions or taxes on repatriation of cash held outside of the U.S. to have a material effect on our overall business, liquidity, financial condition or results of operations for the foreseeable future.
Information Concerning Forward-Looking Statements
Certain matters contained in this report concerning the business outlook, including raw material, energy and other input costs, the anticipated cost savings from our FORCE program, cash flow and uses of cash, growth initiatives, innovations, marketing and other spending, net sales, anticipated currency rates and exchange risks, including the impact in Argentina and Turkey, effective tax rate, contingencies and anticipated transactions of Kimberly-Clark, including dividends, share repurchases and pension contributions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are based upon management's expectations and beliefs concerning future events impacting Kimberly-Clark. 
21

There can be no assurance that these future events will occur as anticipated or that our results will be as estimated.  Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them. 
The assumptions used as a basis for the forward-looking statements include many estimates that, among other things, depend on the achievement of future cost savings and projected volume increases. In addition, many factors outside our control, including the war in Ukraine (including the related responses of consumers, customers, and suppliers and sanctions issued by the U.S., the European Union, Russia or other countries), pandemics (including the ongoing COVID-19 outbreak and the related responses of governments, consumers, customers, suppliers and employees), epidemics, fluctuations in foreign currency exchange rates, the prices and availability of our raw materials, supply chain disruptions, changes in customer preferences, severe weather conditions, government trade or similar regulatory actions, potential competitive pressures on selling prices for our products, energy costs, general economic and political conditions globally and in the markets in which we do business, as well as our ability to maintain key customer relationships, could affect the realization of these estimates.
For a description of certain factors that could cause our future results to differ from those expressed in these forward-looking statements, see Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021 entitled "Risk Factors." Other factors not presently known to us or that we presently consider immaterial could also affect our business operations and financial results.
Item 4.    Controls and Procedures
As of September 30, 2022, an evaluation was performed under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, management, including the Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective as of September 30, 2022. There were no changes in our internal control over financial reporting during the quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
22

PART II – OTHER INFORMATION
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
We repurchase shares of Kimberly-Clark common stock from time to time pursuant to publicly announced share repurchase programs. All our share repurchases during the third quarter of 2022 were made through a broker in the open market.
The following table contains information for shares repurchased during the third quarter of 2022. None of the shares in this table were repurchased directly from any of our officers or directors.
Period (2022)
Total Number
of Shares
Purchased(a)
 Average
Price Paid
Per Share		 Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
Maximum Number
of Shares That May
Yet Be Purchased
Under the Plans or
Programs(b)
July 1 to July 31 46,500  $ 133.97  38,743,681  41,256,319 
August 1 to August 31 69,300  134.05  38,812,981  41,187,019 
September 1 to September 30 76,200  122.16  38,889,181  41,110,819 
Total 192,000 
(a)Share repurchases were made pursuant to a share repurchase program authorized by our Board of Directors on November 13, 2014. This program allows for the repurchase of 40 million shares in an amount not to exceed $5 billion (the "2014 Program").
(b)Includes shares under the 2014 Program, as well as available shares under a share repurchase program authorized by our Board of Directors on January 22, 2021 that allows for the repurchase of 40 million shares in an amount not to exceed $5 billion.
23


Item 6.    Exhibits
(a)Exhibits